Printer Friendly

Active B12: a rapid, automated assay for holotranscobalamin on the Abbott AxSYM analyzer.

Vitamin [B.sub.12] is essential for 1-carbon metabolism and cell division. Vitamin [B.sub.12] deficiency is a major public health issue, particularly amongst the elderly. The clinical consequences of vitamin [B.sub.12] deficiency include megaloblastic anemia and progressive neurologic disease of the central and peripheral nervous systems.

Measurement of the total vitamin B12 concentration in plasma is the current standard clinical test for vitamin [B.sub.12] deficiency; however, a proportion of individuals with vitamin [B.sub.12] concentrations that would be considered deficient exhibit no clinical or biochemical evidence of deficiency (1). Conversely, neuropsychiatric (2) and metabolic (1) abnormalities can occur with plasma vitamin [B.sub.12] concentrations well within the reference interval.

Vitamin [B.sub.12] is bound to 2 proteins in serum, transcobalamin (TC) [3] and haptocorrin (HC). HC binds the majority of circulating vitamin [B.sub.12] (70%- 90%). The exact function of this HC-bound vitamin [B.sub.12] is unknown, but it is believed to be biologically unavailable to most cells (3). The remaining 10%-30% of vitamin [B.sub.12] is bound to holoTC. TC carries the vitamin from its site of absorption to the tissues and delivers the vitamin to cells via a specific receptor with a high affinity for holoTC (4).

Genetic absence of HC is rare but not a serious condition and is usually discovered accidentally (5). On the other hand, the genetic absence or an abnormality of TC manifests as the typical hematologic and neurologic pathologies of vitamin [B.sub.12] deficiency (6). Such deficiency, usually discovered shortly after birth as a failure to thrive, requires aggressive therapy with vitamin [B.sub.12] if long-term and irreversible neurologic damage is to be avoided.

The measurement of total serum vitamin [B.sub.12] suffers from a number of limitations, most particularly that the majority of vitamin [B.sub.12] measured is that bound to HC. Given that holoTC has a shorter circulating half-life than holoHC, the earliest change that occurs when an individual enters a negative vitamin [B.sub.12] balance is very likely to be a decrease in the plasma holoTC concentration. Direct measurement of holoTC has been postulated to provide a better indicator of an individual's vitamin [B.sub.12] status (7).

Although this hypothesis is now nearly 20 years old, only recently have reliable and sensitive methods for estimating holoTC become available (8, 9). Recent studies have suggested that holoTC is both a better early marker for changes in vitamin [B.sub.12] status than total vitamin [B.sub.12] (10-12) and more strongly associated with conditions related to impaired cobalamin function (13). HoloTC concentrations are low in patients with biochemical signs of vitamin [B.sub.12] deficiency (14). Lowvalues have been reported in vegetarians (15,16), vegans (17), and the elderly (18).

Current holoTC assays are manual, however, and not suitable for the clinical laboratory workload. Very recently, investigators developed a novel monoclonal antibody (mAb) with a specificity for holoTC that is at least 100-fold greater than for apoTC (19). This antibody will allow the development of simple direct immunoassays for the quantification of holoTC. Such assays will also avoid the need for the various denaturing treatments required to release vitamin [B.sub.12] from binding proteins used in most vitamin [B.sub.12] assays and thus will remove a possible cause of preanalytical variability.

We describe the characteristics of an assay we have developed for use on an automated immunoassay analyzer (Abbott AxSYM) that is suitable for testing large numbers of samples. We compare results obtained with this assay with those for the current commercially available RIA, together with the expected concentrations in the healthy population and in untreated pernicious anemia patients.

Materials and Methods


The production of mouse antihuman holoTC and antihuman TC antibodies has previously been described (19,20). Human recombinant holoTC and apoTC were from Cobento (21). A sample of purified HC was kindly provided by Ebba Nexo (University of Aarhus, Aarhus, Denmark). We used the holoTC RIA from Axis-Shield Diagnostics and used 0.2-[micro]m OptiLink carboxylate-modified microparticles (Seradyn). We obtained MiniKros hollow-fiber filter modules with a 0.2-[micro]m cutoff from Spectrum Laboratories and alkaline phosphatase (AP) from Biozyme. Sephadex G25 size-exclusion chromatography media was obtained from Sigma-Aldrich and prepared per the manufacturer's instructions.


The AxSYM is an automated, random-access immunoassay analyzer that uses fluorescence polarization immunoassay, microparticle immunoassay, and ioncapture technologies (22).



For a typical 100-mL coating, 28 mL of anti-holoTC mAb (1 g/L) was mixed with 2.5 mL of 100 g/L microparticle solids and 188 mL of 50 mmol/L MES buffer, pH 5.5. The pH of the mixture was checked and adjusted to 5.5 (within 0.1 pH unit) before conjugation. The reaction was started by the addition of 6.3 mL of 50 g/L of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDAC), freshly prepared in water; thus, the final concentrations in the reaction mixture were 0.56 g/L mAb, 5 g/L microparticle solids, and 3.3 mmol/L EDAC in 18.8 mmol/L MES, pH 5.5. This coating mixture was stirred for 1 h at room temperature. The particles were then washed by buffer exchange with diafiltration in 2 coating-mixture volumes of wash buffer (10 mmol/L sodium phosphate buffer, pH 7.2, containing 1 mL/L Tween 20 and 145 mmol/L NaCl). A MiniKros hollow-fiber filter module (0.2-[micro]m cutoff) was used to exchange buffer with the particles. After washing, the particles were exchanged into 2 coating-mixture volumes of capping buffer (40 mmol/L Tris buffer, pH 8.0, 100 mmol/L NaCl, 23 mmol/L EDTA, 10 g/L bovine serum albumin, and 0.9 g/L sodium azide). The particles were then stirred for 1 h at room temperature in the capping buffer. The particles were diluted to 2 coating-mixture volumes in storage buffer (260 g/L sucrose, 40 mmol/L Tris buffer, pH 8.0, 100 mmol/L NaCl, 23 mmol/L EDTA, 10 g/L bovine serum albumin, and 0.9 g/L sodium azide) for a final sucrose concentration of 130 g/L. Finally, the particles were stressed by incubation at 37 [degrees]C for 16-18 h before storage at 2-8 [degrees]C.


The anti-TC mAb was dialyzed against 100 mmol/L triethanolamine buffer, pH 8.4, containing 0.9 mmol/L EDTA and 100 mmol/L NaCl. AP (about 20 g/L) was dialyzed against 30 mmol/L triethanolamine buffer, pH 7.6, containing 3 mol/L NaCl, 50 [micro]mol/L Zn[Cl.sub.2], and 1 mmol/L Mg[Cl.sub.2]. The mAb was activated (by conversion of primary amine groups to sulfhydryl groups) by reaction for 30 min at room temperature with a 300:1 molar ratio of 2-iminothiolane to mAb. The AP was activated by reaction with a 38:1 molar ratio of sulfosuccinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate to AP and mixing at room temperature for 40-45 min. Both reactions were stopped by adding excess glycine. Size-exclusion chromatography on a Sephadex G25 column was used to remove low molecular weight molecules from the preparations and to exchange the mAb and the AP into their respective conjugation buffers. The mAb preparation was exchanged into 100 mmol/L triethanolamine buffer, pH 7.3, containing 0.9 mmol/L EDTA and 100 mmol/L NaCl; the AP preparation was exchanged into 100 mmol/L triethanolamine buffer, pH 7.3, containing 100 mmol/L NaCl, 50 [micro]mol/L Zn[Cl.sub.2], and 1 mmol/L Mg[Cl.sub.2]. We then mixed activated mAb and AP in a 1:1 molar ratio for 60 min at 37 [degrees]C and then quenched the reaction by adding excess maleimide. Finally, we purified the mAbAP conjugate and exchanged the buffer by size-exclusion chromatography in 100 mmol/L triethanolamine buffer, pH 7.0, containing 100 mmol/L NaCl, 50 [micro]mol/LZn[Cl.sub.2],1 mmol/L Mg[Cl.sub.2], and 1 g/L sodium azide.


HoloTC calibrators were prepared gravimetrically from a 50-nmol/L stock solution of recombinant human holoTC. The purity of the recombinant holoTC was evaluated (a) by denaturing electrophoresis on a polyacrylamide gel containing sodium dodecyl sulfate and (b) spectroscopically by measuring the ratio of the protein component to the vitamin [B.sub.12] component, the requirement being a mean (SD) [A.sub.280]/[A.sub.362] absorbance ratio of 2.3 (0.1), which indicates a purity of >97% (23). The concentration of the holoTC stock solution was calculated (a) from the absorbance at 362 nm with a molar absorptivity of 30 000 [(mol/ L).sup.-1][cm.sup.-1] (24) and (b) by measurement in a vitamin [B.sub.12] assay (Elecsys [B.sub.12] immunoassay, Roche Diagnostics). The final formulation of the calibrators contained holoTC diluted in sodium phosphate buffer (10 mmol/ L), pH 7.2, bovine serum albumin (2.5 g/L), and an excess of vitamin [B.sub.12] (50 nmol/L). The calibrator concentrations were finally readjusted with a panel of serum samples of known holoTC concentration to correct for differences in ionic strength and pH between the calibrator buffer and serum samples; the interaction between holoTC and the holoTC-specific antibody is sensitive to differences in ionic strength and pH (19).


The control material was prepared from pooled samples of human serum adjusted with recombinant human holoTC and the sodium phosphate buffer, pH 7.5, to the desired concentration. The holoTC concentrations of the control material (low and high controls) differed somewhat between preparations.


Fig. 1 illustrates the assay protocol. The sampling probe pipets the sample or calibrator (0, 8, 16, 32, 64, and 128 pmol/L) and all AxSYM Active [B.sub.12] reagents required for a test into different wells of a reaction vessel. The diluted sample and microparticles coated with anti-holoTC mAb are combined in the sample well of the reaction vessel. The holoTC present in the sample binds to the coated microparticles. The anti-TC mAb:AP conjugate is pipetted into a second well of the reaction vessel, Active [B.sub.12] wash buffer (4.0 g/L Triton X100 and 1 g/L Proclin 300 in water) is pipetted into a third well, and AxSYM Matrix Cell wash solution (Abbott) is pipetted into a fourth well. The reaction vessel is immediately transferred into the Processing Center of the AxSYM instrument. The Processing Probe performs additional pipetting in the Processing Center. A 90-[micro]L aliquot of the reaction mixture containing microparticles and bound holoTC is transferred to the glass-fiber matrix of the Matrix Cell. The Matrix Cell is washed with 50 [micro]L of Active [B.sub.12] wash buffer and 2 X 50[micro]L of AxSYM Matrix Cell wash solution, and 60 [micro]L of the anti-TC mAb:AP conjugate is dispensed onto the Matrix Cell and binds to the captured holoTC. The substrate (4-methylumbelliferyl phosphate) is added after a second wash step, and the rate of substrate dephosphorylation by AP is measured by the optical assembly of the microparticle immunoassay instrument. Calibration used 4-parameter logistic curve fitting.

The sample requirement is 200 [micro]L.


For studies of the reference interval and method comparison, serum samples were provided by Dr. J. M. Pekelharing, Medical Laboratories, Reiner de Graaf Hospital, Delft, The Netherlands. Samples were collected from healthy volunteer hospital staff; there were no other exclusion or inclusion criteria. Samples were stored frozen at -25 [degrees]C to -30 [degrees]C until testing. The studies were approved by the regional ethics committee, and the participants gave informed consent. A total of 292 samples were measured once. The participant's age was available for 278 individuals, and sex data were available for 276 individuals (78 males and 198 females).

For the method comparison, we reassayed 204 samples from the reference population with the HoloTC RIA, a manual RIA, with the protocol supplied by the manufacturer (Axis-Shield) (8).


We also analyzed 5 samples from untreated pernicious anemia patients; these samples were kindly provided by Angel F. Remacha, Hospital de Sant Pau, Barcelona, Spain. The patients had given informed consent.


The detection limit (mean + 2 SDs for the zero calibrator) was determined on 2 AxSYM instruments, each of which used 2 lots each of the 0- and 8-pmol/L calibrators. We conducted 3 runs each of 10 replicates for the 0-pmol/L calibrator and 4 replicates for the 8-pmol/L calibrator.

Assay imprecision (CV) was evaluated according to NCCLS (currently CLSI) protocol EP5-A2 (25). We tested 2 samples each in the normal (49 pmol/L) and low-normal (23 pmol/L) regions of the reference interval. Because only the lower part of the reference interval is diagnostically important, we did not include a concentration above the upper limit of the reference interval. We measured the holoTC concentration twice daily in duplicate for 20 days on 2 different AxSYM instruments (n = 160 for each sample).

We estimated the working range (CV <20%) for the assay by measuring the holoTC concentration in 2-5 replicates of 12 undiluted and 4 diluted serum samples in 5 analytical runs conducted over 5 days with 2 different instruments. We took 20-50 measurements of each serum sample.

Analytical selectivity was evaluated in 5 separate experiments by measuring the cross-reactivity with apoTC (500 pmol/L) and HC (5 nmol/L) in AxSYM Line Diluent (Abbott).

To analyze the effect of dilution on assay linearity, we mixed 3 samples of pooled sera with 72, 87, and 103 pmol/L holoTC with AxSYM Active B12 Low Control (20 pmol/L) at1:4, 2:3, 3:2, and 4:1 ratios of the serum sample volume to the volume of Low Control. All samples were measured in quadruplicate.

To investigate the use of alternative blood-collection tubes, we analyzed 11 samples with holoTC concentrations of 37-124 pmol/L with serum tubes, gel-separator serum tubes, lithium-heparin plasma tubes, and EDTA plasma tubes (Becton-Dickinson).


To establish a reference interval, we measured holoTC concentrations in serum samples from 292 apparently healthy volunteers (age range, 21-70 years).


We calculated total and intraassay imprecision according to CLSI protocol EP5-A2, as described above (25), and assessed assay linearity with regression analysis. To investigate the reference interval, we normalized data by logarithmic transformation before analysis. We used the Student f-test and ANOVA with the post hoc Bonferroni correction. We used Deming regression analysis to compare methods and analyzed residuals with the Bland-Altman plot.


Data were analyzed with Analyse-it (Analyse-it Software) for Microsoft Excel and GraphPad Prism (GraphPad Software).

Results and Discussion

A typical calibration curve for the AxSYM Active B12 assay (Fig. 2) shows the relationship between the rate of fluorescent probe production and holoTC concentration. Fitting with the 4-parameter logistic curve produced a good fitting accuracy ([r.sup.2] = 1.00) and only a small (<5%) fitting error (Fig. 2, inset). The assay features a turnaround time of 20 min and an assay throughput of 45 tests/h.

The mean detection limit was 0.08 pmol/L (observed range, 0.03-0.14 pmol/L). Total imprecision was 6.3%-8.5%, and intraassay imprecision was 3.4%-5.1% (see Table S1 in the Data Supplement that accompanies the online version of this article at http:// The working range (CV <20%) was at least 3-107 pmol/L (Fig. 3). The assay was linear over at least the range of 20103 pmol/L [slope (SD), 1.005 (0.032); y-intercept, 2.8 (1.9) pmol/L; [r.sup.2] = 0.98] (Fig. 4). Measurements of diluted serum samples yielded concentrations that were 104%-114% of the expected values within the working range of the assay.




Serum contains 2 proteins (apoTC and HC) that have the potential to cross-react with a holoTC-specific antibody. ApoTC is the vitamin [B.sub.12]-transporting protein TC uncomplexed with vitamin [B.sub.12]. HC is a closely related vitamin [B.sub.12]-transporting protein in serum. The cross-reactivities of apoTC and HC were 0.08% and 0.004%, respectively (see Table S2 in the online Data Supplement). We observed no interference with the following substances added to serum samples: bilirubin, 684 [micro]mol/L (0.4 g/L); hemoglobin, 5 g/L; triglycerides, 17mmol/L (15 g/L); total protein, 95 g/L; erythrocytes, 4 mL/L; and rheumatoid factor, 500 kIU/L. The measured holoTC values were 92%-110% of the expected values.

HoloTC concentrations measured with the AxSYM Active [B.sub.12] assay were similar after sample processing with serum, gel-separator serum, and lithiumheparin plasma tubes but were significantly higher after processing with EDTA plasma tubes (139% relative to serum tubes). This effect was not attributable to a direct effect of EDTA on holoTC binding to the anti body, because that interaction is unaffected by EDTA (19). It also cannot be attributed to an effect on AP, because the EDTA-containing plasma is washed off before the AP-conjugated second antibody is added. Whatever the cause, the Active B12 assay cannot be recommended for EDTA-treated plasma.

The comparison of the AxSYM Active B12 assay and the HoloTC RIA yielded a regression equation with a slope (SD) of 0.98 (0.03), ay-intercept of 4.7 (2.0) pmol/L, and a S value of 11.4 pmol/L (Fig. 5). The values obtained with the AxSYM Active [B.sub.12] assay were slightly higher than those obtained with the RIA, as is seen in the Bland-Altman plot (Fig. 5, inset). The principles of the 2 assays are different. The AxSYM Active B12 assay directly measures holoTC in the sample with an immobilized mAb specific for holoTC. In the RIA, an immobilized TC-specific mAb captures the total TC (apoTC plus holoTC) in the sample; the vitamin [B.sub.12] bound by holoTC is then released and measured with a conventional competitive assay protocol for vitamin [B.sub.12].


An ANOVA of the log-transformed data revealed holoTC concentration to be weakly dependent on age but not on sex. Further analysis revealed that the positive correlation with age was confined to women. The 95% reference interval was 19-134 pmol/L (mean, 50 pmol/L), which is similar to the reference interval (24-157 pmol/L) previously obtained with the commercial holoTC assay, HoloTC RIA (8).

Serum samples were obtained from 5 patients who had received a clinical diagnosis of pernicious anemia but had not yet been treated. HoloTC and serum vitamin [B.sub.12] were measured with the AxSYM Active B12 and Abbott AxSYM B12 assays, respectively. The holoTC and serum vitamin [B.sub.12] concentrations for the 5 patients were <3,3,4,3, and 4 pmol/L, and 62,92,62, 87, and 49 pmol/L, respectively.

In conclusion, AxSYM Active B12 is a sensitive and highly specific high-throughput assay for quantitative measurement of the biologically active fraction of vitamin [B.sub.12], holoTC, in serum and plasma.

Grant/funding Support: None declared.

Financial Disclosures: The authors are employees of Axis-Shield, which has proprietary rights to AxSYM Active B12.

Received September 4, 2007; accepted December 5, 2007.

Previously published online at DOI: 10.1373/clinchem.2007.096784


(1.) Green R. Metabolite assays in cobalamin and folate deficiency. Baillieres Clin Haematol 1995; 8:533- 66.

(2.) Lindenbaum J, Healton EB, Savage DG, Brust JC, Garrett TJ, Podell ER, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988;318:1720-8.

(3.) Nexo E. Cobalamin binding proteins. In: Krautler B, Arigoni D, Golding BT, eds. Vitamin [B.sub.12] and [B.sub.12]-proteins. Weinheim, Germany: Wiley-VCH, 1998:461-75.

(4.) Quadros EV, Nakamura Y, Sequeira JM. The binding properties of the human receptor for the cellular uptake of vitamin [B.sub.12]. Biochem Biophys Res Commun 2005;327:1006-10.

(5.) Carmel R, Herbert V. Deficiency of vitamin [B.sub.12] binding alpha globulins in two brothers. Blood 1969;33:1-12.

(6.) Hakami N, Neiman PE, Cannelos GP, Lazerson J. Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. N Engl J Med 1971;285:1163-70.

(7.) Herzlich B, Herbert V. Depletion of serum holotranscobalamin II: an early sign of negative vitamin [B.sub.12] balance. Lab Invest 1988;58:332-7.

(8.) Ulleland M, Eilertsen I, Quadros EV, Rothenberg SP, Fedosov SN, Sundrehagen E, Orning L. Direct assay for cobalamin bound to transcobalamin (holo-transcobalamin) in serum. Clin Chem 2002; 48:526-32.

(9.) Nexo E, Christensen AL, Hvas AM, Petersen TE, Fedosov SN. Quantification of holotranscobalamin, a marker of vitamin [B.sub.12] deficiency. Clin Chem 2002;48:561-2.

(10.) Nexo E, Hvas AM, Bleie O, Refsum H, Fedosov SN, Vollset SE, et al. Holo-transcobalamin is an early marker of changes in cobalamin homeostasis. A randomized placebo-controlled study. Clin Chem 2002;48:1768-71.

(11.) Bor MV, Nexo E, Hvas AM. Holo-transcobalamin concentration and transcobalamin saturation reflect recent vitamin [B.sub.12] absorption than does serum vitamin [B.sub.12]. Clin Chem 2004; 50:1043-9.

(12.) Clarke R, Sherliker P, Hin H, Nexo E, Hvas AM, Schneede J, et al. Detection of vitamin [B.sub.12] deficiency in older people by measuring vitamin [B.sub.12] or the active fraction of vitamin [B.sub.12], holotranscobalamin. Clin Chem 2007;53:963-70.

(13.) Herrmann W, Obeid R, Schorr H, Geisel J. The usefulness of holotranscobalamin in predicting vitamin [B.sub.12] status in different clinical settings. Curr Drug Metab 2005;6:47-53.

(14.) Obeid R, Jouma M, Herrmann W. Cobalamin status (holo-transcobalamin, methylmalonic acid) and folate as determinants of homocysteine concentration. Clin Chem 2002;48:2064-5.

(15.) Herrmann W, Obeid R, Schorr H, Geisel J. Functional vitamin [B.sub.12] deficiency and determination of holotranscobalamin in populations at risk. Clin Chem Lab Med 2003;41:1478-88.

(16.) Herrmann W, Schorr H, Obeid R, Geisel J. Vitamin [B.sub.12] status, particularly holotranscobalamin II and methylmalonic acid concentrations, and hyperhomocysteinemia in vegetarians. Am J Clin Nutr 2003;78:131-6.

(17.) Lloyd-Wright Z, Hvas AM, Moller J, Sanders TAB, Nexo E. Holotranscobalamin as an indicator of dietary vitamin [B.sub.12] deficiency. Clin Chem 2003; 49:2076-8.

(18.) Miller JW, Garrod MG, Rockwood AL, Kushnir MM, Allen LH, Haan MN, Green R. Measurement of total vitamin [B.sub.12] and holotranscobalamin, singly and in combination, in screening for metabolic vitamin [B.sub.12] deficiency. Clin Chem 2006;52: 278-85.

(19.) Orning L, Rian A, Campbell A, Brady J, Fedosov SN, Bramlage B, et al. Characterization of a monoclonal antibody with specificity for holotranscobalamin. Nutr Metab (London) 2006; 3:3.

(20.) Quadros EV, Rothenberg SP, McLoughlin P. Characterization of monoclonal antibodies to epitopes of human transcobalamin II. Biochem Biophys Res Commun 1996;222:149-54.

(21.) Fedosov SN, Fedosova NU, Nexo E, Petersen TE. Conformational changes of transcobalamin induced by aquocobalamin binding: mechanism of substitution of the cobalt-coordinated group in the bound ligand. J Biol Chem 2000;275: 11791-8.

(22.) Smith J, Osikowicz G. Abbott AxSYM random and continuous access immunoassay system for improved workflow in the clinical laboratory. Clin Chem 1993;36:2063-9.

(23.) Quadros EV, Rothenberg SP, Pan YC, Stein S. Purification and molecular characterization of human transcobalamin II. J Biol Chem 1986;261: 15455- 60.

(24.) Fedosov SN, Berglund L, Nexo E, Petersen TE. Sequence, S-S bridges, and spectra of bovine transcobalamin expressed in Pichia pastoris. J Biol Chem 1999;274:26015-20.

(25.) NCCLS. Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Second Edition. NCCLS document EP5-A2 (ISBN 1-56238-542-9). NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 U S A, 2004.

Jeff Brady, [1 [dagger]] Lesley Wilson, [1] Lynda McGregor, [1] Edward Valente, [1] and Lars Orning [2] *

[1] Axis-Shield Diagnostics, Ltd., Dundee, Scotland, UK. [2] Axis-Shield POC, Oslo, Norway.

[[dagger]] Current address: Translational Medicine Research Collaboration, Sir James Black Centre, University of Dundee, Dow St., Dundee DD1 5EH, Scotland, UK.

* Address correspondence to this author at: Axis-Shield POC, Ulvenveien 87, PO Box 206 Okern, N-0510 Oslo, Norway. Fax 47-22700-770; e-mail

[3] Nonstandard abbreviations: TC, transcobalamin; HC, haptocorrin; mAb, monoclonal antibody; AP, alkaline phosphatase.
COPYRIGHT 2008 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:General Clinical Chemistry
Author:Brady, Jeff; Wilson, Lesley; McGregor, Lynda; Valente, Edward; Orning, Lars
Publication:Clinical Chemistry
Date:Mar 1, 2008
Previous Article:Reference intervals for serum creatinine concentrations: assessment of available data for global application.
Next Article:Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis.

Related Articles
Abbott Announces Alliance With Toshiba In Clinical Chemistry
False-positive AxSYM cardiac troponin I results in a 53-year-old woman. (Case Reports).
Performance evaluation and subsequent clinical experience with the Abbott automated architect STAT troponin-I assay.
Comparison of II human insulin assays: implications for clinical investigation and research.
Multicenter analytical evaluation of an enzymatic method for the measurement of plasma homocysteine and comparison with HPLC and immunochemistry.
False increase of cardiac troponin I with heterophilic antibodies.
Rapid, automated assay for progesterone on the Abbott AxSYM[TM] analyzer.
Proficiency testing of creatine kinase and creatine kinase-2: the experience of the Ontario Laboratory Proficiency Testing Program.
Development and multisite evaluation of an automated assay for [B.sub.12] on the Abbott AxSYM analyzer.
Methodology and subspecialty consolidation in the clinical laboratory.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters